Novimmune

Novimmune is a privately held Swiss pharmaceutical development company focusing on monoclonal antibody therapies for treatment of immune-related diseases.[1] The company was founded in 1998.[2]

Novimmune has six publicly disclosed drug in their pipeline:

No drugs have been approved yet.

References

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.